The Experts below are selected from a list of 6477 Experts worldwide ranked by ideXlab platform
Jeanluc Reny - One of the best experts on this subject based on the ideXlab platform.
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, Frits R. Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, F R Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
Valder R Arruda - One of the best experts on this subject based on the ideXlab platform.
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, Frits R. Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, F R Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
prothrombin mutant Factor V Leiden and thermolabile Variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in brazil
American Journal of Hematology, 1998Co-Authors: Fernanda L Andrade, Joyce M Annichinobizzacchi, Sara T O Saad, Fernando Ferreira Costa, Valder R ArrudaAbstract:The preValence of the prothrombin gene Variant (allele 20.210 A), Factor V Leiden mutation, and homozygosity for transition 677C-->T in the methylenetetrahydrofolate reductase (MTHFR) gene was determined among patients with sickle cell disease (SCD). The group included 73 patients with median age of 32.3 years with a diagnosis of sickle cell anemia in 53 patients, hemoglobinopathy SC in 16 patients, and four with S/beta(0) thalassemia. Vascular complications such as ischemic stroke or deep Vein thrombosis were diagnosed in nine patients. Heterozygosity for the prothrombin gene Variant or Factor V Leiden mutation was identified in four patients. HoweVer, only one patient, who deVeloped ischemic stroke, was identified as a carrier of Factor V Leiden mutation. None of the patients presented homozygosity for the thermolabile Variant of the MTHFR. These data suggest a low clinical impact of inherited hypercoagulability risk Factors in deVeloping thrombosis, occlusiVe stroke, or mortality data among patients with SCD in Brazil.
Joseph Emmerich - One of the best experts on this subject based on the ideXlab platform.
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, Frits R. Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, F R Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
Andreas Hillarp - One of the best experts on this subject based on the ideXlab platform.
-
Factor V Leiden and prothrombin gene mutation risk Factors for osteonecrosis of the femoral head in adults
Clinical Orthopaedics and Related Research, 2004Co-Authors: Anders Bjorkman, Andreas Hillarp, Peter Svensson, Isabella M Burtscher, Anders Runow, Goran BenoniAbstract:The purpose of the current study was to determine whether Factor V Leiden and the prothrombin 20210A gene mutation are risk Factors for osteonecrosis of the femoral head in different etiologic groups of osteonecrosis in adults and whether patients with idiopathic osteonecrosis of the femoral head haVe a higher frequency of thromboembolic eVents compared with the general population. We inVestigated 63 adult patients with nontraumatic osteonecrosis of the femoral head for etiologic Factors, such as corticosteroid medication and alcohol abuse, and the occurrence of Factor V Leiden and the prothrombin 20210A gene mutation. In 35 patients, the disease was considered idiopathic and 10 of these patients (29%) had Factor V Leiden or the prothrombin 20210A gene mutation or both. Mutations in Factor V or the prothrombin 20210A gene were significantly more frequent in patients with idiopathic osteonecrosis than in a population of healthy control subjects (odds ratio, 2.7; 95% confidence interVal range, 1.2-5.8) and in patients with osteonecrosis caused by corticosteroid medication or alcohol abuse (odds ratio, 10.8; 95% confidence interVal range, 1.4-84). 36% of patients with a gene mutation had had a thromboembolic eVent compared with 8% of patients without a gene mutation. Thromboembolic eVents were more common among patients with idiopathic osteonecrosis (17%) compared with the general population (4%) and with patients with osteonecrosis caused by corticosteroid medication or alcohol abuse (7%).
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, Frits R. Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, F R Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
F R Rosendaal - One of the best experts on this subject based on the ideXlab platform.
-
combined effect of Factor V Leiden and prothrombin 20210a on the risk of Venous thromboembolism pooled analysis of 8 case control studies including 2310 cases and 3204 controls
Thrombosis and Haemostasis, 2001Co-Authors: Joseph Emmerich, Tony Cumming, Valder R Arruda, Andreas Hillarp, Valerio De Stefano, Maurizio Margaglione, Marco Cattaneo, F R Rosendaal, Jeanluc RenyAbstract:Factor V Leiden and Factor II G20210A mutations are two frequent genetic risk Factors inVolVed in Venous thromboembolism (VTE). The goal of this pooled analysis of 8 case-control studies, comprising a total of 2310 cases and 3204 controls, was to precisely estimate the risk of VTE in patients bearing both mutations (double heterozygotes). Odds ratios for VTE were 4.9 (95% CI; 4.1-5.9) for the Factor V Leiden and 3.8 (3.0-4.9) for the Factor II G20210A mutation. Fifty-one cases (2.2%) and none of the controls were double heterozygotes. The odds ratio for Venous thrombosis in double heterozygotes was 20.0 (11.1-36.1). TwelVe percent of patients heterozygous for Factor V Leiden were also heterozygous for Factor II G20210A and conVersely 23% of patients heterozygous for Factor II G20210A were also heterozygous for Factor V Leiden. Furthermore, in this large population we analyzed the effect of oral contraceptiVe (OC) in women carrying one of these mutations. Odds ratio for VTE associated with OC was 2.29 (1.72-3.04). In Factor V Leiden carriers using OC, the odds ratio for VTE was 10.25 (5.69-18.45). The odds ratio of the association of Factor II mutation and OC use was 7.14 (3.39-15.04). Finally, we also confirmed that the frequency of Factor V Leiden was lower in patients with pulmonary embolism than in patients with deep Vein thrombosis without PE (odds
-
thermolabile methylenetetrahydrofolate reductase and Factor V Leiden in the risk of deep Vein thrombosis
Thrombosis and Haemostasis, 1998Co-Authors: Leo A J Kluijtmans, Pieter H Reitsma, Henk J Blom, Den M Heijer, Sandra G Heil, F R RosendaalAbstract:Mild hyperhomocysteinemia is an established risk Factor for both arteriosclerosis and thrombosis, and may be caused by genetic and enVironmental Factors. Methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the coFactor for the methylation of homocysteine to methionine. IndiViduals with the thermolabile Variant of MTHFR haVe decreased MTHFR actiVities, resulting in eleVated plasma homocysteine concentrations. A homozygous 677C T transition in the MTHFR gene has recently been identified as the cause of reduced enzyme actiVity and thermolability of the protein. We studied the frequency of the homozygous mutant (+/+) genotype in 471 patients with deep-Vein thrombosis and 474 healthy controls enrolled in The Leiden Thrombophilia Study (LETS), its interaction with Factor V Leiden, and assessed the association between the MTHFR genotypes and plasma homocysteine concentration. Homozygosity for the 677C T polymorphism was obserVed in 47 (10%) patients, and in 47 (9.9%) controls (OR 1.01 [95% CI: 0.7-1.5]). No modified risk of the (+/+) genotype was obserVed in carriers of Factor V Leiden. Our data suggest that, although the homozygous mutant genotype is associated with eleVated plasma homocysteine concentrations, this homozygous mutation itself is not a genetic risk Factor for deep-Vein thrombosis, irrespectiVe of Factor V Leiden genotype.
